Life science focused Vida Ventures is advancing on its goal of raising $600 million for its second VC fund. According to a recent filing, Vida has raised more than $536 million of its goal.
The company has secured commitments from 109 investors for the fund. It is unclear from the filing if $600 million is a hard cap on the fund.
Vida's website lists 12 companies in its portfolio. This includes: Allogene, Praxis and Peloton Therapeutics. It was recently announced that Peloton will be acquired by Merck for an upfront payment of $1.05 billion. Peloton shareholders will be elligible to receive an additional $1.15 billion contingent upon successful achievement of future regulatory and sales milestones.
